Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Sarcoma

3691 - Preoperative hypofractionated radiotherapy (RT) in patients with locally advanced myxoid liposarcomas: interim analysis of prospective phase II clinical trial

Date

22 Oct 2018

Session

Poster Discussion session - Sarcoma

Topics

Radiation Oncology

Tumour Site

Sarcoma

Presenters

Hanna Kosela Paterczyk

Citation

Annals of Oncology (2018) 29 (suppl_8): viii576-viii595. 10.1093/annonc/mdy299

Authors

H.M. Kosela Paterczyk1, M. Spalek2, M. Wagrodzki3, A. Borkowska2, A. Szumera-Cieckiewicz3, A. Cieszanowski4, T. Morysinski1, J. Palucki4, P.L. Rutkowski5

Author affiliations

  • 1 Department Of Soft Tissue/bone Sarcoma And Melanoma, The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), 02-781 - Warsaw/PL
  • 2 Department Of Radiotherapy, Maria Sklodowska-Curie Institute - Oncology Center, 02-781 - Warsaw/PL
  • 3 Department Of Pathology, Maria Sklodowska-Curie Institute - Oncology Center, 02-781 - Warsaw/PL
  • 4 Radiology, Maria Sklodowska-Curie Institute - Oncology Center, 02-781 - Warsaw/PL
  • 5 Soft Tissue/bone Sarcoma And Melanoma, The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), 02-781 - Warsaw/PL
More

Resources

Abstract 3691

Background

Myxoid liposarcoma (MLPS) has been reported to be more radiosensitive compared with other soft tissue sarcomas. The main objective of the study is to assess the efficacy of hypofractionated radiotherapy in preoperative setting in patients with locally advanced primary MLPS.

Methods

Single-arm prospective clinical trial enrolls MLPS patients for preoperative 5x5 Gy RT with 6-8 weeks gap between RT end and surgery. The endpoints of the study are the rate of early wound healing complications and 5- year local control rate.

Results

Since the study opening in May 2015 19 patients (pts) have been included: 16 finished the whole planned protocol treatment; 3 pts are awaiting surgery now. All but one of the patients had the tumors located on the lower limb. The median size of the tumor was 14 cm (range 5-20 cm), 40% of the patients had high grade tumors as assessed by FNCLCC and 40% of the patient had more than 5% od round cell component. Early RT tolerance was good. EORTC grade 1 radiation dermatitis developed in 10 pts and grade 3 in 1 patient. Postoperative wound complications occurred in 3 pts as wound dehiscence and prolonged wound healing. R0 margins were achieved in all but one patient 1 patient which had an R1 resection margin. None of the patient had local recurrence.

Conclusions

Preoperative hypofractionated RT with a long gap between the radiotherapy and surgery is a feasible method of the management of MLPS providing a good local control and low rates of treatment toxicity.

Clinical trial identification

Legal entity responsible for the study

Hanna Koseła-Paterczyk, Piotr Rutkowski.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

P.L. Rutkowski: Honoraria: Bristol-Myers Squibb, Roche, Novartis, Merck, Sharp & Dohme, GlaxoSmithKline; Paid consulting role: Bristol-Myers Squibb, Roche, Merck, Sharp & Dohme, Blueprint Medicines, Amgen; Speakers’ bureau: Novartis, Pfizer, Merck, Sharp & Dohme; Institutional research funding: Bristol-Myers Squibb, Novartis; Travel expenses: Novartis, Orphan Drugs. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.